- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.05. | Enlaza Therapeutics secures $100m in Series A funding | ||
| 01.05. | Bayer and Evotec link to develop precision cardiology therapeutics | ||
| 01.05. | Eli Lilly reports 67% increase in Q1 2024 net income | ||
| 01.05. | Novartis and PeptiDream expand peptide discovery deal | ||
| 30.04. | Pfizer and Genmab's Tivdak wins full FDA approval for cervical cancer | ||
| 30.04. | CHMP recommends AstraZeneca's Truqap and Faslodex combo approval | ||
| 30.04. | Accord BioPharma's HERCESSI secures FDA approval | ||
| 30.04. | Repertoire and Bristol Myers Squibb link on autoimmune disease vaccines | ||
| 30.04. | FDA approves X4 Pharmaceuticals' WHIM syndrome drug | ||
| 29.04. | Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn | ||
| 29.04. | Biodexa gains license for polyposis asset as stock more than doubles | ||
| 29.04. | "Profound concern" over WHO's pandemic agreement, says AIDS charity | ||
| 29.04. | AstraZeneca's Fasenra: Approval for asthma may initiate COPD approval | ||
| 29.04. | BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding | ||
| 29.04. | Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data | ||
| 29.04. | Duchenne Muscular Dystrophy: the global clinical trials landscape 2024 | ||
| 29.04. | Sino Biological concludes SignalChem acquisition for $48m | ||
| 29.04. | PharmaLink partners with Recall Results on safety of drugs | ||
| 29.04. | Pierre Fabre's vibegron gains CHMP positive opinion for OAB | ||
| 29.04. | Pfizer receives FDA approval for haemophilia B gene therapy | ||
| 29.04. | Cell and gene therapy companies trip at scalability hurdle | ||
| 26.04. | The privileged status of orphan medicines in Germany | ||
| 26.04. | Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks | ||
| 26.04. | Merck's net income for Q1 2024 increases by 69% to $4.76bn | ||
| 26.04. | Multiply Labs and GenScript partner on cell isolation automation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
